Aliqopa
Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% ...
DECEMBER 28, 2021
Copanlisib-Rituximab Combo Improves Survival for Indolent NHL
Combining copanlisib with rituximab significantly extends progression-free survival in patients with indolent ...
JUNE 18, 2021
FDA Approves Aliqopa for Follicular Lymphoma
Bayer's Aliqopa (copanlisib) has been granted accelerated approval to treat patients with relapsed follicular ...
SEPTEMBER 25, 2017
Load more